ARTICLE | Company News
BioTime ophthalmic news
November 19, 2012 8:00 AM UTC
BioTime will purchase 87,456 shares of its Cell Cure NeuroSciences Ltd. subsidiary in exchange for 906,735 BioTime shares at $3.86, or about $3.5 million. The price is a 5.1% premium based BioTime's close on Nov. 6, before the deal was announced. Following the purchase, BioTime will own approximately 62.6% of outstanding shares of Cell Cure. Cell Cure was a subsidiary of ES Cell International Pte. Ltd. BioTime acquired ES Cell in 2010 (see BioCentury, May 10, 2010). ...